Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

T cells are crucial for immune functions to maintain health and prevent disease. T cell
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …

Cancer immunotherapy aims to promote the activity of cytotoxic T lymphocytes (CTLs) within
a tumour, assist the priming of tumour-specific CTLs in lymphoid organs and establish …

Dendritic cells (DCs) possess the ability to integrate information about their environment and
communicate it to other leukocytes, shaping adaptive and innate immunity. Over the years, a …

Dendritic cells are powerful antigen-presenting cells that are essential for the priming of T
cell responses. In addition to providing T-cell-receptor ligands and co-stimulatory molecules …

Although conventional innate immune stimuli contribute to immune activation, they induce
exhausted immune cells, resulting in suboptimal cancer immunotherapy. Here we suggest a …

During the past two decades, interleukin-12 (IL-12) has emerged as one of the most potent
cytokines in mediating antitumor activity in a variety of preclinical models. Through …

Abstract Interleukin 12 (IL-12) seemed to represent the ideal candidate for tumor
immunotherapy, due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T …

Alzheimer's disease (AD) is a chronic neurodegenerative disease characterized by the
accumulation of amyloid plaques and neurofibrillary tangles in the brain. The AD …

Dendritic cells (DC) are professional antigen presenting cells comprising a variety of
subsets, as either resident or migrating cells, in lymphoid and non-lymphoid organs. In the …